key: cord-0825908-mkmsh14p
authors: Alanazi, Asma
title: COVID-19 and the Role of Stem Cells
date: 2021-08-26
journal: Regen Ther
DOI: 10.1016/j.reth.2021.08.008
sha: 31a9b9573254e7f4398e862713c9312a28b2baff
doc_id: 825908
cord_uid: mkmsh14p

There is currently an ongoing coronavirus respiratory disease (COVID-19) pandemic that is caused by SARS-CoV-2 virus, which emerged out of Wuhan, China. In severe cases, the disease can progress to respiratory distress, hypoxia, and multi-organ failure, all of which are associated with high mortality. Mesenchymal stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. MSCs have demonstrated their impressive ability to inhibit lung damage, reduce inflammation, attenuate the immune response, and aid with alveolar fluid clearance. Studies that investigated the use of MSCs and exosome cells derived from MSCs in treating COVD-19 patients have encouraging results. The conclusion of the results of four clinical studies, as presented in this review article, is reduced patient mortality in more than half of the subjects who were administered MSCs or exosomes derived from MSCs, intravenously, positioning these cells as a possible therapeutic solution for COVID-19. While the studies do have limitations, they do provide a stepping stone based on different approaches in the search for treatment to save patients.

Coronavirus disease 2019 (COVID-19) is a respiratory disease that causes patients to have pneumonia-like symptoms. An outbreak of this disease started in 2019 in Wuhan, China, and has since then spread to Europe, United States, and the rest of the world, evolving into a deadly pandemic that has killed more than one million people. This disease is caused by the virus of the name severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Zhou et al., 2020; . Hospitalizations are required for certain subjects (approximately 15% to 20%), J o u r n a l P r e -p r o o f mostly those who tend to have underlying health conditions of lung, heart, liver, kidney, hypertension, diabetes, obesity, and those who are aged > 65 years (Centers for Disease Control and Prevention, 2020; Berlin et al., 2020) . About 5% of patients experience severe respiratory difficulties, septic shock, and multiple organ failure (Moore et al., 2020) .

The fight against COVID-19 relies heavily on the need to regenerate damaged lung tissue and to treat inflammation. This is where the need arises for mesenchymal stem cells (MSCs) (Caplan, 2017) . These cells can be extracted from different parts of the body. Starting in 2020, there have been multiple ongoing trials for testing the efficacy of MSCs on patients with severe COVID-19, most of which produced promising results (Atala et al., 2020; Leng et al., 2020; ) , making them the most likely cells of choice for cell-based therapy trials (Liang et al., 2020) .

Patients with debilitating COVID-19 infection experience a severe cytokine storm, hyperinflammation, and immunothrombosis; many of them end up developing severe pneumonia. Lung injury can result, paving the path for respiratory failure through the development of acute respiratory distress syndrome (ARDS) (Kox et al., 2020; Lucas et al., 2020) . About 67% of subjects with with underlying health conditions and COVID-19-induced ARDS end up being critically ill with severe respiratory distress (Zhu et al., 2020) . ARDS is characterized by an overreaction of the immune system. The result is a massive inflammatory cell infiltration and release of pro-inflammatory cytokines. In these severe cases, the overactive immune system damages lung tissue so patients with ARDS need high-flow oxygen therapy, intensive care, and mechanical ventilation (Centers for Disease Control and Prevention, 2020;

Berlin et al., 2020).

When a cytokine storm starts, it is accompanied by more aggressive tissue-based immunity, leading to increased tissue damage. During this massive overreaction by the immune system, there is secretion of myeloid/macrophage-derived cytokines, including exacerbated production of interleukin (IL)-6, IL-8, IL-1α, IL-1β, tumor necrosis factor-alpha (TNF-α), granulocyte colony-stimulating factor (GSCF), CCL-2, CCL-3, and CCL-5. These proinflammatory cytokines attract macrophages, monocytes, and T cells to the infection cell. What follows is an excessive inflammatory response which leads to further accumulation of immune cells in the lungs, promoting additional inflammation in lung tissue (Tay et al., 2020) .

A percentage of COVID-19-induced ARDS patients end up with multiple organ failure and death, tied to the damage sustained by the cytokine storm. Mortality in patients with COVID-19 and ARDS was reported to be 52.4% . For patients who survive these complications, significant morbidity follows because of neuromuscular weakness, myopathy, and residual lung fibrosis. Such consequences can persist up to five years after recovering from ARDS, resulting in increased healthcare utilization and cost (Herridge et al., 2011) .

MSCs are multipotent cells capable of self-renewal and can give rise to unique, diagnosed with COVID-19-induced ARDS, whose mean age was 53.8 years and who were admitted into intensive care units (ICUs). The purpose was to test the safety and potential adverse events following transplantation of prenatal MSCs in the subjects. Before the administration of MSCs, the subjects were critically ill, dyspneic, and required mechanical ventilation. They received three intravenous infusions (200 × 10 6 cells) every day for a total of 600 × 10 6 UC-MSCs (in 6 cases) and placental-MSCs (in 5 cases). After 48 -96 hours from the first infusion, there was reduced dyspnea and increased SpO2 in seven patients. From the total of 11 patients, six were discharged from the ICUwith significant improvementswithin 2 to 7 days of infusion. However, five cases died 4 -19 days after the first cell infusion.

In the 6 patients who survived the ICU discharge, it was observed that there were significant reductions in pro-inflammatory biomarkers, of TNF-α (P < 0.01), IL-8 (P = 0.02), and C-reactive protein (P = 0.01). Serum IL-6 levels decreased in five patients (P = 0.06) and

INF-γ levels decreased in four patient (P = 0.14). The findings of the study do support the conclusion that intravenous injection of prenatal MSCs is safe, tolerable, and can improve respiratory symptoms in some critically ill COVID-19 patients.

This study does have limitation , however, due to the low number of patients. In addition, there was a lack of a case-matched control group, which limited the researchers' ability to compare the ICU course and mortality of the MSC-treated cases with similar patients who had J o u r n a l P r e -p r o o f COVID-19-induced ARDS. One more limitation was that there wasn't data regarding the reduction in C-reactive protein and pro-inflammatory cytokines in non-survivor subjects. There is a need for large, randomized controlled trials to fill in the gap of knowledge about the therapeutic potential of MSCs for the treatment of this disease.

From BM-MSCs. The researchers in this study administrated exosomes that were derived from BM-MSCs, intravenously, to COVID-19 patients. What these exosomes contain are several chemokines, growth factors, microRNAs, and mRNA that can exert paracrine and endocrine anti-inflammatory, regenerative, and immunomodulatory effects (Zhao et al., 2019) . Before this study, exosomes were an unexplored treatment option for COVID-19, but preclinical studies of these bone-derived exosomes were done intravenously in animal models who suffered from acute lung injury, ARDS, asthma, and other inflammatory diseases, with successful results of edema clearance and sequelae of cytokine storm (Katsha et al., 2011) . In the study by Sengupta et al. (2020) , the first clinical study to date using BM-MSCsderived exosomes as treatment for a disease in an inpatient setting, 24 patients with COVID-19 were given exosomes delivered at single intravenous dose. They were followed and evaluated for safety from days 1 to 14 post-treatment. After 14 days, 17 patients recovered, but 3 of the patients remained critically ill and the other 4 passed away for reasons unrelated to the treatment.

In subjects who made it to recovery, oxygenation was restored with an improvement of the average pressure of arterial O2 to a fraction of inspired oxygen ratio (increase of 192%; P < 0.001). There were also significant reductions in neutrophil count, along with statistically significant increases in lymphocyte count. This study demonstrated significant reversal of hypoxia, along with immune system downregulation and a reduction of the cytokine storm in patients, after just a single dose, placing them as a promising potential to be implemented. This J o u r n a l P r e -p r o o f

Placental stem cells

Regen med therapeutic opportunities for fighting COVID-19. stem cells translational med

Severe Covid-19

Umbilical cord mesenchymal stromal cells with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized open-label clinical study to assess safety and impact on insulin secretion

Mesenchymal stem cells; time to change the name! stem cells translational med

The MSC: an injury drugstore

Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells

Human term placental cells: phenotype, properties and new avenues in regenerative medicine

Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19)

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection, a hint for COVID-19 treatment

Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID-19-associated organ failure. Stem cells translational medicine

Impact of age on human adipose stem cells for bone tissue engineering

Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cordderived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLa-Haploidentical Stem-Cell Transplantation

A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation

Isolation and characterization of a bat SARSlike coronavirus that uses the ACE2 receptor

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial

Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints

Mesenchymal stem cell-based therapy of inflammatory lung disease: current understanding and future perspectives

Functional disability 5 years after acute respiratory distress syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Role of platelet-derived growth factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target

Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastaseinduced emphysema model

Cell-based therapies for COVID-19: proper clinical investigations are essential

Cytokine levels in critically ill patients with COVID-19 and other infections

Mesenchymal stromal cells for sepsis and septic shock: lessons for treatment of COVID-19. Stem cells translational med

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Potential application of mesenchymal stem cells in acute lung injury

Transplantation of mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Intratracheal transplantation of amnionderived mesenchymal stem cells ameliorates hyperoxia-induced neonatal hyperoxic lung injury via aminoacyl-peptide hydrolase

Clinical remission of a critically ill COVID-19 pneumonia

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virusassociated acute lung injury

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs)

Amnion-derived pluripotent/multipotent stem cells

Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study

Cytokine release syndrome in severe COVID-19

iPSCs: a minireview from bench to bed, including organoids and the CRISPR system

Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Dervied Stem Cells

Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders

Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentation into multiple skin cell type

The long path of human placenta, and its derivatives, in regenerative medicine

The trinity of COVID-19: immunity, inflammation, and intervention

Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult marine heart

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy

Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood

Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Human umbilical cord-derived mesenchymal stem cells for acute respiratory distress syndrome

Nrf2 transfection enhances the efficacy of human amniotic mesenchymal stem cells to repair lung injury induced by lipopolysaccharide

Emerging role of mesenchymal stem cell-derived exosomes in regenerative medicine

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A novel coronavirus from patients with pneumonia in China